Cephalon announced positive results from a phase 2 clinical trial of Nuvigil (armodafinil) tablets as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.
The eight-week, double-blind, placebo-controlled study evaluated the efficacy and safety of Nuvigil (150 mg/day) as an adjunctive therapy to mood stabilizers in 257 patients with bipolar I disorder, who experienced a major depressive episode that was not completely managed by their other treatments. Patients in the study taking Nuvigil as adjunctive therapy showed improvement of depressive symptoms (p=0.042) as measured on the primary endpoint – the 30-Item Inventory of Depressive Symptomatology, Clinician-Rated (IDS-C30) scale. The IDS-C30 scale is an instrument used to evaluate depressive episodes and associated symptoms.
For more information call (800) 896-5855 or visit www.cephalon.com.